



PTO/SB/08A/B (09-05)

Approved for use through 03/31/2007. OMB 0651-0031
U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1448/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Application Number	10/584,805
		Filing Date	June 28, 2006
		First Named Inventor	Menachem Rubinstein
		Art Unit	1646
		Examiner Name	Not Yet Assigned D. Jiang
Sheet	1	of	3
		Attorney Docket Number	30694/42147

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code* (if known)			
		US-2002/0098185	07-25-2002	Sims et al.	
		6,605,280	08-12-2003	Novick et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No.	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁴
		Country Code ² -Number ² -Kind Code ³ (if known)	MM-DD-YYYY			
	*	WO-WO92/16221	10-01-1992	Thompson et al.		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 608. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. * CITE NO.: Those application(s) which are marked with an single asterisk (*) next to the Cite No. are not supplied (under 37 CFR 1.98(e)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T ²
		* Cohen et al., "Bringing the Clinical Experience with Anakinra to the Patent" Rheumatology, Oxford University Press, London, GB, vol. 42, no. SUPPL 2, May 2003 (2003-5), pages I136-I140		
		* Wheelock, "Interferon-like virus-inhibitor induced in human leukocytes by phytohemagglutinin," Science, 149:310-311 (1965)		
		* Billiau, "Interferon-gamma: biology and role in pathogenesis," Adv. Immunol., 62:61-130 (1996)		
		* Boehm et al., "Cellular responses to interferon-gamma," Annu. Rev. Immunol., 15:749-795 (1997)		
		* Tau et al., Biologic Functions of the IFN-gamma receptors," Allergy, 54(12):1233-1251 (1999)		
		* Patrone et al., "Genes expressed during the IFN gamma-induced maturation of pre-B cells," Mol. Immunol., 38:597-606 (2002)		
		* Rasschaert et al., Global profiling of double stranded RNA- and IFN-gamma-induced genes in rat pancreatic beta cells," Diabetologia, 46(12):1641-1657 (2003)		
		* Kwon et al., "Synergistic cytokine-induced nitric oxide production in human alveolar epithelial cells," Nitric Oxide, 3(4):348-357 (1999)		
		* Visser et al., "Chemokines produced by mesothelial cells: huGRO-alpha, IP-10, MCP-1 and RANTES," Clin. Exp. Immunol., 112(2):270-275 (1998)		
		* Doukas et al., IFN-gamma enhances endothelial activation induced by tumor necrosis factor but not IL-1," J. Immunol., 145(6):1727-1733 (1990)		
		* Ohmori et al., The interferon-stimulated response element and a kappa B site mediate synergistic induction of murine IP-10 gene transcription by IFN-gamma and TNF-alpha," J. Immunol., 154(10):5235-5244 (1995)		
		* Faure et al., "Bacterial lipopolysaccharide and IFN-gamma induce Toll-like receptor 2 and Toll-like receptor 4 expression in human endothelial cells: role of NF-kappa B activation," J. Immunol., 166(3):2018-2024 (2001)		
Examiner Signature			Date Considered	

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Application Number	10/584,805
				Filing Date	June 28, 2006
				First Named Inventor	Menachem Rubinstein
				Art Unit	0
				Examiner Name	Not Yet Assigned
Sheet	2	of	3	Attorney Docket Number	30694/42147

	* Male et al., "Synergy between interferons and monokines in MHC induction on brain endothelium," <i>Immunol. Lett.</i> , 17(3):267-271 (1988)	
	* Cheshire et al., "Synergistic activation of NF-kappaB by tumor necrosis factor alpha and gamma interferon via enhanced I kappaB alpha degradation and de novo I kappaBbeta degradation," <i>Mol. Cell. Biol.</i> , 17(11):6746-6754 (1997)	
	* Novick et al., "A novel IL-18BP ELISA shows elevated serum IL-18BP in sepsis and extensive decrease of free IL-18," <i>Cytokine</i> , 14(6):334-342 (2001)	
	* Hurgin et al., "The promoter of IL-18 binding protein: activation by an IFN-gamma -induced complex of IFN regulatory factor 1 and CCAAT/enhancer binding protein beta," <i>Proc. Natl. Acad. Sci. USA</i> , 99(26):16957-16962 (2002)	
	* Novick et al., "Interleukin-18 binding protein: a novel modulator of the Th1 cytokine response," <i>Immunity</i> , 10(1):127-136 (1999)	
	* Joosten et al., "Association of interleukin-18 expression with enhanced levels of both interleukin-1beta and tumor necrosis factor alpha in knee synovial tissue of patients with rheumatoid arthritis," <i>Arthritis Rheum.</i> , 48(2):339-347 (2003)	
	* Mantovani et al., "Negative regulators of the interleukin-1 system: receptor antagonists and a decoy receptor," <i>Int. J. Clin. Lab. Res.</i> , 26:7-14 (1996)	
	* Plater-Zyberk et al., "Therapeutic effect of neutralizing endogenous IL-18 activity in the collagen-induced model of arthritis," <i>J. Clin. Invest.</i> , 108(12):1825-1832 (2001)	
	* Nolsoe et al., "Mutation scan of a type 1 diabetes candidate gene: the human interleukin-18 binding protein gene," <i>Ann. N.Y. Acad. Sci.</i> , 1005:332-339 (2003)	
	* Conli et al., "Induction of Interferon-gamma inducing factor in the adrenal cortex," <i>J. Biol. Chem.</i> , 272(4):2035-2037 (1997)	
	* Pizarro et al., "IL-18, a novel immunoregulatory cytokine, is up-regulated in Crohn's disease: expression and localization in intestinal mucosal cells," <i>J. Immunol.</i> , 162(11):6829-6835 (1999)	
	* Rubinstein et al., "Convenient assay for interferons," <i>J. Virol.</i> , 37(2):755-758 (1981)	
	* Kim et al., "Structural requirements of six naturally occurring isoforms of the IL-18 binding protein to inhibit IL-18," <i>Proc. Natl. Acad. Sci. USA</i> , 97(3):1190-1195 (2000)	
	* Burts et al., "The trials of anakinra," <i>The Lancet</i> , Vol. 364, September 4, 2004, pp. 827-828.	
	* Kary, S. et al., "Anakinra: The First Interleukin-1 Inhibitor in the Treatment of Rheumatoid Arthritis," <i>JCP</i> , Vol. 57(3), April 2003, pp. 231-234.	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /DJ/

Examiner Signature	/Dong Jiang/	Date Considered	10/08/2008
--------------------	--------------	-----------------	------------